hotspot -WSS

hotspot

author：hotspot 2025-08-23 08:57:27 - browse：4137

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Researchers tackle phage therapy hurdles for wider adoption

WSS

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Reporting on presidential health from Reagan to Trump and Biden

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Secretariat’s lessons for human medicine

Measles policy set amid Florida outbreak alarms vaccine proponents

In rare move, senator releases unverified FBI source report alleging Biden bribe

entertainment

hotspot

hotspot

Medical records are filled with copy

Ukraine seeks to reclaim its role as a hub for clinical trials

Malaria cases in Florida and Texas: Here’s what you need to know

Measles policy set amid Florida outbreak alarms vaccine proponents

ChatGPT in medicine: STAT answers readers' burning questions

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

DIEP, the 'gold standard' of breast reconstruction, is under threat

In 'major milestone,' FDA approves first cell therapy for solid tumors

Malaria cases in Florida and Texas: Here’s what you need to know

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

leisure time

Judge denies Trump's request for new trial in E. Jean Carroll case

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

FDA warns medical device makers about rise in fabricated data

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

FDA warns medical device makers about rise in fabricated data

explore

explore

leisure time

knowledge